Risk conferred by T2D modified by HbA1c in heart failure

October 12, 2017

(HealthDay)—For patients with heart failure, the risks conferred by type 2 diabetes (T2D) can be stratified by glycemic control and drug treatments, according to a study published online Oct. 11 in JACC: Heart Failure.

Claire A. Lawson, Ph.D., R.N., from the University of Keele in the United Kingdom, and colleagues compared patients with versus those without T2D for risk of all-cause first hospitalization and death in an incident database cohort. T2D was stratified by categories of hemoglobin A1c (HbA1c) or drug treatments.

The researchers found that T2D was associated with the risk of first hospitalization and mortality in heart failure (adjusted odds ratios [aORs], 1.29 and 1.24, respectively). Compared with the reference heart failure group without T2D, stratification of T2D by HbA1c levels showed U-shaped associations with both outcomes. The highest-risk categories were HbA1c >9.5 percent and <5.5 percent (aORs: hospitalization, 1.75 and 1.42; mortality, 1.3 and 1.29, respectively). There was a correlation for T2D group with change in HbA1c of >1 percent decrease with hospitalization and mortality (aORs, 1.33 and 1.36). T2D group with reducing drug treatments were associated with hospitalization and mortality (aORs, 2.13 and 2.09).

"In the general HF [heart failure] population, T2D stratified by and drug treatments showed differential risk associations," the authors write. "Routine measures of dynamic diabetes status provide important prognostic indication of poor outcomes in HF."

Explore further: Risk factors explain most heart failure risk in incident A-fib

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Risk factors explain most heart failure risk in incident A-fib

June 19, 2017
(HealthDay)—Four modifiable factors account for most of the population attributable risk of heart failure among women with new-onset atrial fibrillation (AF), according to a study published online June 14 in JACC: Heart ...

Impact of T2DM meds on heart failure hospitalization explored

January 19, 2016
(HealthDay)—For patients with type 2 diabetes, there is no association between hospitalization for heart failure and treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) versus sulfonylureas (SUs) or treatment with ...

Improved glycemic control with eradication of hepatitis C

July 7, 2017
(HealthDay)—For patients with type 2 diabetes, direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) is associated with improved glycemic control and reduced antidiabetic medication use, according to a study ...

Simple tool accurately predicts 30-day mortality for patients with acute heart failure in the ER

October 2, 2017
A simple tool using readily available data can accurately estimate the 30-day mortality risk for patients admitted to the emergency department with acute heart failure. Emergency department physicians may consider using this ...

Cardiorespiratory fitness impacts BMI-related heart failure risk

April 7, 2017
(HealthDay)—Higher body mass index (BMI) is associated with increased risk of heart failure, which is largely explained by differences in cardiorespiratory fitness (CRF), according to a study published online April 5 in ...

Beta-blocker use not linked to reduced mortality after AMI

June 1, 2017
(HealthDay)—β-blocker use is not associated with reduced mortality after acute myocardial infarction (AMI) without heart failure or left ventricular systolic dysfunction (LVSD), according to a study published in the June ...

Recommended for you

Research suggests new pathways for hyperaldosteronism

December 7, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP), in collaboration with researchers at Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the ...

One-dose gene therapy produces clotting factor, safely stops bleeding in hemophilia B patients

December 6, 2017
A team of gene therapy researchers has reported positive results in a phase 1/2 clinical trial for the inherited bleeding disorder hemophilia B. A single intravenous infusion of a novel bioengineered gene therapy treatment ...

Clot-busting drugs not recommended for most patients with blood clots

December 6, 2017
Not all patients with blood clots in their legs - a condition known as deep vein thrombosis - need to receive powerful but risky clot-busting drugs, according to results of a large-scale, multicenter clinical trial.

Mitochondrial protein in cardiac muscle cells linked to heart failure, study finds

December 5, 2017
Reducing a protein found in the mitochondria of cardiac muscle cells initiates cardiac dysfunction and heart failure, a finding that could provide insight for new treatments for cardiovascular diseases, a study led by Georgia ...

Blood pressure declines 14 to 18 years before death

December 4, 2017
Blood pressure in the elderly gradually begins to decrease about 14 or so years before death, according to a new study published today in the JAMA Internal Medicine.

Study links common male medical condition and vascular disease

December 1, 2017
Men who suffer symptoms from varicoceles, enlarged veins in the scrotum, are more likely to develop vascular disease and metabolic disease, such as diabetes, according to a study by Stanford University School of Medicine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.